There are countless reasons why I will be attending the ISPE 2017 Europe Annual Conference, but for the sake of time, I’ve narrowed it down to my top three.
April 4th – Accelerated Development – Afternoon Session The industry and regulatory speakers will touch on trends and potential solutions, including faster selection of drug candidates and clinical trials with Advanced Therapy Medicinal Products (ATMP).
April 5th – GDP & GMP Annex 15 Risk Management – Morning Session You will get brand new regulatory updates and hear various case studies. One focus will be on Direct-to-Patient supplies. Share and learn more in a planned risk based distribution workshop.
April 5th – Patient Centricity & Innovative Supply Chain Approaches – Afternoon Session Listen to patient representatives, clinical supply chain and technology experts and discuss how value can be created for patients in clinical trials.
I’m looking forward to this unique opportunity to enhance my technical knowledge, exchange ideas with my peers, and gain insight from industry experts. I’m looking forward to seeing you at the 2017 ISPE Europe Annual Conference! By: Jens Mattuschka World Courier, an AmerisourceBergen company RVP | Nordics, Central and Eastern Europe
The following blog post was provided by Peyton Myers, an undergraduate student at Appalachian State University. Myers attended the 2023 ISPE Annual Meeting & Expo in Las Vegas as an ISPE Foundation Professional Development Grant recipient.
The integration of data science in biopharmaceutical manufacturing, emphasizing data quality, tech transfer efficiency, and process optimization, is the heart of this track. Led by industry experts, discussions explore leveraging digital twins, predictive analytics, and continuous improvement initiatives. Additionally, interactive roundtable discussions provide attendees with a dynamic forum...
The pharmaceutical sector stands at a crossroads of immense possibilities. We are witnessing an unprecedented surge in innovation, fueled by a remarkable partnership between industry and regulatory authorities. For example, there are initiatives fostered by the US Food and Drug Administration (US FDA) to promote innovation with programs such as CATT (CBER Advanced Technologies Team) and ETP...